首页> 外文期刊>The journal of sexual medicine >Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation
【24h】

Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation

机译:PDE5治疗勃起功能障碍的辍学:预测因素研究和停药原因的定性分析

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction. Phosphodiesterase type 5 inhibitors (PDE5) are currently the first line treatment for erectile dysfunction (ED). However, previous research shows that PDE5 treatments have high discontinuation rates. Understanding the reasons for discontinuing PDE5 will be necessary to optimize the response to treatment. Aim. The main goals were: (i) to analyze discontinuation rate of PDE5; (ii) to identify the discontinuation predictors; and (iii) to study the reasons for discontinuation using a qualitative methodology. Main Outcome Measures. The PDE5 discontinuation rates, predictors, and reasons for discontinuation treatment. Methods. A total of 327 men with clinical diagnosis for ED who had been treated with PDE5 were successfully interviewed by telephone, after giving their informed consent by snail mail. Telephone interviews, concerning their ongoing treatment, were carried out using a standardized questionnaire form with quantitative and qualitative items. Participation rate was 71.8%. Results. Of the total sample, 160 men (48.9%) had discontinued PDE5 treatment. The discontinuation rate was higher among men with diabetes (73%) and in iatrogenic group (65%), and lower in venogenic etiology (38.7%). We differentiated three groups of men who discontinued treatment (i) during the first 3 months (55.1%); (ii) between 4 and 12 months (26.9%); and (iii) after a period of 12 months (18%). Qualitative analyses revealed diverse reasons for discontinuation: non-effectiveness of PDE5 (36.8%), psychological factors (e.g., anxiety, negative emotions, fears, concerns, dysfunctional beliefs) (17.5%), erection recovery (14.4%), and concerns about the cardiovascular safety of PDE5 (8.7%) were the most common. Older men and men whose partners were involved in the treatment, were less likely to discontinue treatment. Conclusion. Half the subjects discontinued medication. Mostly, there was a combination of factors that led to discontinuation: non-effectiveness and psychosocial factors appear to be the main reasons. Addressing those factors will allow following up with appropriate focus on relevant topics in order to improve compliance.
机译:介绍。磷酸二酯酶5型抑制剂(PDE5)目前是勃起功能障碍(ED)的一线治疗。但是,先前的研究表明,PDE5治疗的停用率很高。了解中止PDE5的原因对于优化对治疗的反应很有必要。目标。主要目标是:(i)分析PDE5的终止率; (ii)确定停产预测指标; (iii)使用定性方法研究停产的原因。主要观察指标。 PDE5停药率,预测因素和停药原因。方法。在通过蜗牛邮件获得知情同意后,通过电话成功采访了总共327名接受过PDE5治疗的ED临床诊断男性。关于他们正在接受的治疗的电话采访使用标准化的问卷形式进行,其中包含定量和定性的项目。参与率为71.8%。结果。在总样本中,有160名男性(48.9%)停止了PDE5治疗。糖尿病男性(73%)和医源性人群(65%)的停药率较高,而静脉病因病因(38.7%)较低。我们对三组在开始的头三个月停止治疗的男性进行了区分(i)(55.1%); (ii)4至12个月(26.9%); (iii)12个月后(18%)。定性分析显示了中止治疗的多种原因:PDE5无效(36.8%),心理因素(例如焦虑,消极情绪,恐惧,担忧,功能失调的信念)(17.5%),勃起恢复(14.4%)和对以下方面的担忧PDE5的心血管安全性(8.7%)是最常见的。年龄较大的男性及其伴侣参与治疗的人中止治疗的可能性较小。结论。一半的受试者停药。通常,有多种因素导致停药:无效和社会心理因素似乎是主要原因。解决这些因素将有助于对相关主题进行适当的关注,以提高合规性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号